- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01022749
Efficacy Safety Study of Flu Vaccine in Immunodepression Patients (MICIVAX)
Prospective, Multicentre, Open-label Study Evaluating the Immunogenicity and Safety of Influenza Vaccine in Patients With Inflammatory Bowel Disease (IBD) Receiving or Not Immunosuppressive Therapy
The primary purpose of the study is to compare the efficacy and safety of influenza vaccine in patients with inflammatory bowel disease (IBD) receiving immunosuppressive therapy with patients not receiving immunosuppressants .
The main objective of the study is to evaluate the humoral immunogenicity of influenza vaccination in patients with IBD
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Annual vaccination against influenza is recommended for those at high risk of complications, particularly among patients with immunodeficiency including those resulting from immunosuppressive treatments administered for a chronic inflammatory bowel disease (IBD). However, published data showing that influenza vaccination coverage is low in this population (<30%) due to lack of data on the effectiveness of vaccination in these patients and the theoretical risk of negative impact on the evolution of IBD.
To improve influenza vaccination coverage of the population treated by immunosuppressants for a chronic IBD, it is essential to have data on the effectiveness of vaccination in these populations.
The research aims to evaluate the immunogenicity of influenza vaccination in patients followed for a chronic IBD.
Factors in choice of study population were as follows:
- IBD is a common disease. Among the inflammatory diseases treated with immunosuppressants and reaching patients under 65 years, IBD are among the most frequent. They result from an abnormal immune response to gut flora and their management often requires the prescription of immunosuppressive drugs (azathioprine, methotrexate, in particular) and more recently TNF-blockers;
- the existence of vaccine recommendations published recently for specific patients on immunosuppressive therapy at greatest risk of complications related to influenza;
- the fact that vaccinations have not been implicated in the pathogenesis of the disease;
- data showing that vaccination recommendations are poorly followed in this population. A recently published work found vaccination coverage against influenza of only 28% in a cohort of 169 patients treated for IBD;
The methodology chosen is a phase III, prospective, open, vaccine trial. The primary endpoint is the humoral immunogenicity induced by the vaccine.
The study is scheduled on 2 successive years to assess the value of annual vaccination repeated in this population treated with immunosuppressants.
There is a benefit for patients to participate in this study because they are all vaccinated against influenza and will benefit from a clinical and laboratory monitoring in this study. Moreover, these patients are taken to be vaccinated in the event of a pandemic influenza
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75014
- CIC Vaccinologie Hopital Cochin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria :
- informed consent signed
- Age between 18 to 64
- Patient suffering from chronic inflammatory bowel disease (Crohn's disease, ulcerative colitis, or indeterminate colitis)
- For patients receiving at least one immunosuppressive or anti-TNF therapy: treatment introduced for at least 3 months
- Patient willing to participate in the study throughout its duration and acceptance procedures related to the study (blood samples, self questionnaires, nasal swab and telephone follow-up)
Exclusion criteria :
- Patient treated by corticosteroid alone without immunosuppressive or anti-TNF
- For women, being pregnant or positive pregnancy test
- Known allergy to any component of the study vaccine or a history of hypersensitivity reaction to influenza vaccination
- Fever (at least 37.5°C measured orally) or acute infection in the week prior to vaccination
- Received influenza vaccination in the 6 months preceding enrollment
- Known history of progressive neuropathy or Guillain-Barre
- Known infection with HIV and/or HBV (Ag-HBs positive) and/or HCV
- Other causes of severe immune deficiency
- Cellular therapy, immunoglobulin infusions, of blood products or monoclonal antibodies (except anti-TNF) in the 3 months prior to vaccination
- Patient deprived of freedom by an administrative or court order
- Patient non affiliated to a health social security system
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 2
patients with IBD receiving immunosuppressants (TNF blockers excluded) (n=100)
|
MUTAGRIP (2009-2010 winter) VAXIGRIP (2010-2011 winter)
|
Experimental: 3
patients with IBD receiving immunosuppressants including TNF blockers (n=100)
|
MUTAGRIP (2009-2010 winter) VAXIGRIP (2010-2011 winter)
|
Experimental: 1
patients with IBD not receiving immunosuppressant (n=100)
|
MUTAGRIP (2009-2010 winter) VAXIGRIP (2010-2011 winter)
|
Active Comparator: 4
patients with IBD receiving immunosuppressants including TNF blockers (n=20)
|
patients who received the vaccine anti-H1N1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Seroconversion rate
Time Frame: 3-4 weeks after vaccination
|
Seroconversion rate in the overall population, defined as the geometric mean titers ratio post / pre-vaccination for each of the three vaccine strains
|
3-4 weeks after vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Seroconversion factor
Time Frame: 3 weeks and 6 months after vaccination
|
The seroconversion factor obtained for each of the three vaccine strains will be compared between each of the three groups (patients not receiving treatment, patients receiving immunosuppressants and patients receiving immunosuppressants including TNF) defined as the geometric mean titers ratio post / pre-vaccination for each of the three vaccine strains
|
3 weeks and 6 months after vaccination
|
Seroprotection rate against the three vaccine strains
Time Frame: 3 or 4 weeks after of vaccination
|
The seroprotection rate (defined as the proportion of subjects attaining an anti-hemagglutinin titer ≥1:40) obtained 3-4 weeks after flu vaccination, against the three vaccine strains
|
3 or 4 weeks after of vaccination
|
Seroprotection rate in the general population
Time Frame: 3 weeks and 6 months after vaccination
|
The seroprotection rate in the general population and according to the three groups of patients
|
3 weeks and 6 months after vaccination
|
Seroconversion rate, geometric mean titers ratio before and after vaccination by haemagglutination inhibition assay
Time Frame: after 3 weeks of vaccination
|
The seroconversion rate, geometric mean titers ratio before and after vaccination by haemagglutination inhibition (HI) assay before and after vaccination
|
after 3 weeks of vaccination
|
Comparison of seroprotection rates for each of the three vaccine strains obtained in each of three groups
Time Frame: 3 weeks and 6 months of vaccination
|
Comparison of seroprotection rates for each of the three vaccine strains obtained in each of three groups (patients not receiving treatment, patients receiving immunosuppressants and patients, receiving immunosuppressants including TNF)
|
3 weeks and 6 months of vaccination
|
Comparison of seroconversion factors obtained after 1 or 2 vaccinations in each of three groups of inflammatory bowel disease (IBD) and in the entire population
Time Frame: After 3 weeks of vaccination
|
After 3 weeks of vaccination
|
|
Number of influenza episodes and confirmed flu during each influenza peak season
Time Frame: 6 months after vaccination
|
6 months after vaccination
|
|
Occurrence of medical visits, emergency room visits, hospital admissions and deaths throughout the course of the study
Time Frame: 18 months after vaccination
|
18 months after vaccination
|
|
Occurrence and intensity of local and general adverse events within 5 days after vaccine administration
Time Frame: 5 days after vaccination
|
5 days after vaccination
|
|
Search of the determining factors to the influenza vaccine response
Time Frame: 18 months after vaccination
|
Search of the determining factors to the influenza vaccine response: sex, age, previous vaccination against influenza, chronic smoking, the presence of other comorbidities (diabetes, renal failure, cirrhosis, ..), the nature of the IBD, the nature of the treatment of IBD and their duration, the number of immunosuppressive treatments associated and Disease Activity Index score of IBD at the vaccination time
|
18 months after vaccination
|
Sub-immunological study
Time Frame: 6 months after vaccination
|
Sub-immunological study each year of the study, the first and the second year (n=60, 20 patients per group): To determine if the LT-CD4 induction at J21-28 is correlated with the antibody anti-vaccines concentration measured within 6 months.
To determine if the basal concentrations of anti-flu LT-CD4 at J21-J28 is correlated with the antibody anti-vaccines concentrations measured within 6 months.
|
6 months after vaccination
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Odile LAUNAY, MD PhD, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P 070165
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Disease (IBD)
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
Icahn School of Medicine at Mount SinaiNorthwestern University; The Cleveland Clinic; University of California, Davis; RxHealt...RecruitingInflammatory Bowel Disease (IBD)United States
-
Nemours Children's ClinicNASPGHAN FoundationCompletedInflammatory Bowel Disease (IBD)United States
-
University of Wisconsin, MadisonTerminatedInflammatory Bowel Disease (IBD)United States
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States
-
Assiut UniversityNot yet recruitingIBD-Inflammatory Bowel Disease
-
Children's Mercy Hospital Kansas CityMedtronic - MITGCompleted
-
Zhongshan Hospital Xiamen UniversityCompletedInflammatory Bowel Disease(IBD)China
-
University College, LondonUnknownInflammatory Bowel Disease (IBD)
-
4SC AGCompletedInflammatory Bowel Disease (IBD)Germany, Bulgaria, Romania
Clinical Trials on Vaccine
-
Butantan InstituteUniversity of Sao Paulo; Hospital Universitario da USPCompleted
-
Sinovac Biotech Co., LtdCompleted
-
GlaxoSmithKlineCompletedMalaria | Malaria VaccinesGhana, Burkina Faso
-
University of OxfordMalaria Research and Training Center, Bamako, MaliRecruiting
-
GlaxoSmithKlineIQVIA, USAActive, not recruitingChickenpoxTaiwan, Poland, United States, Estonia, Puerto Rico, Mexico
-
Sun XinActive, not recruitingVaccine Adverse ReactionChina
-
GlaxoSmithKlineCompletedInfections, PapillomavirusFinland
-
University of California, San FranciscoCompletedHematopoietic Stem Cell TransplantUnited States
-
University of PretoriaUniversity of StellenboschActive, not recruiting
-
China National Biotec Group Company LimitedPeking University; Wuhan Institute of Biological Products Co., Ltd; Guizhou Center... and other collaboratorsCompletedEnterovirus Infections | InfluenzaChina